Clinical Trial: Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07368803) titled 'Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection' on Jan. 19.

Brief Summary: The primary objective of this study is to evaluate the safety of iNeo-Vac-R01, an individualized mRNA therapeutic technology based on tumor neoantigens, for the adjuvant treatment of patients with biliary malignant tumors after radical resection.

Study Start Date: Sept. 11, 2025

Study Type: INTERVENTIONAL

Condition: Biliary Malignant Tumors

Intervention: BIOLOGICAL: iNeo-...